The prevalence of hepatic and thyroid toxicity associated with imatinib treatment of chronic myeloid leukaemia: a systematic review.
Mansour TobaiqyNawal HelmiKathrine MaclureSylvia SaadePublished in: International journal of clinical pharmacy (2023)
High frequency of mild and severe hepatotoxicity, associated with imatinib in CML patients, was reported in the published literature. Low numbers of mild and manageable thyroid toxicity events were reported.
Keyphrases
- high frequency
- end stage renal disease
- chronic myeloid leukemia
- transcranial magnetic stimulation
- newly diagnosed
- oxidative stress
- chronic kidney disease
- ejection fraction
- systematic review
- drug induced
- dendritic cells
- prognostic factors
- risk factors
- peritoneal dialysis
- bone marrow
- randomized controlled trial
- immune response
- patient reported outcomes
- combination therapy
- oxide nanoparticles